

Nine months turnover at 25.9 M€

Radiology: important base effect during the 3rd quarter and delivery delays over the 4th quarter without impact on the 2022 exercise thanks to a sustained order book

Sustained progression of the **Bone densitometry** activity at the end of September and solid order book for the end of the year

Diagnostic Medical Systems Group (Euronext Growth Paris - FR0012202497 - DGM) publishes its consolidated turnover for the nine first months of the 2022 exercise (period between January 1st to September 30th, 2022).

Non audited consolidated data in M€ IFRS standard	2019	2020	2021	2022	<i>Variation</i>
1 st quarter turnover	6.5	7.6	9.0	8.9	-1%
2 nd quarter turnover	7.5	8.0	9.3	9.7	+4%
3 rd quarter turnover	7.3	7.9	9.9	7.4	-26%
9-months turnover	21.4	23.5	28.2	25.9	-8%

During the 3rd quarter of its 2022 exercise, DMS Group recorded a consolidated turnover of 7.4 M€, a decrease of -26% in comparison with the 3rd quarter 2021.

As announced at the end of September, to face the supply difficulties, especially for some electronic components or parts during the last few months, DMS Imaging restructured its production schedule during summer (mainly in July and August 2022), leading to delivery delays from the 3rd to the 4th quarter 2022. These delays will have almost no impact on the expected level of activity over the entire exercise thanks to a sustained order book.

DMS Imaging also reminds that the 3rd quarter 2021 was a record quarter with an exceptional level of activity for the period, resulting from an important delivery of radiology tables globally, as part of a World Bank call for tenders.

At the end of the nine first months of the exercise, the consolidated turnover is established at 25.9 M€, a limited decrease of -8% in comparison with the same period last year, and a +6% growth neutralized by the exceptional contract. As a reminder, DMS Group sold at the beginning of the year 2022 the DMS Wellness division, which realized a turnover of 0.2 M€ over the nine first months of the exercise 2021.

Comments by activity

At the end of the nine first months of the exercise, the DMS Imaging division recorded a consolidated turnover of 25.5 M€, a decrease of -8% compared to the same period last year.

- In Radiology, the nine-months turnover reaches 21.0 M€ (-13%).

Following the extension of the distribution agreement with Fujifilm, DMS Imaging sold its first Platinum DRF X-ray table in the area Africa - Middle East during the 3rd quarter 2022. This new geographic market addressed by Fujifilm, constitutes a new growth vector for DMS Imaging.

During the 3rd quarter 2022, DMS Imaging also won, for a period of 4 years, the UniHA (cooperative of French public hospital buyers) referencing, 1st French public purchaser in the health sector. This referencing reinforces the positioning of DMS Imaging as French leader on the market segment of remote-controlled radiology tables.

Over the nine first months of the exercise, the turnover from distribution agreements (Fujifilm, Carestream and Canon) grew by +30%, and now represent 57% of the total radiology activity, mainly in France and in the United States.

- In Bone densitometry, the activity maintained its good dynamic during the 3rd quarter 2022, growing by +18%. Over the nine first months of the exercise, this activity now reaches a turnover of 4.5 M€, a sustained growth of +30%, explained in part by export sales.

The turnover of the **DMS Biotech** division is established 0.5 M€ over nine months in 2022, slightly growing by +3% compared with the same period in 2021.

Perspectives

In Radiology, at the occasion of the French Days of Radiology (JFR), which took place from October 7th to 10th in Paris, DMS Imaging and its partners made several presentations of the new radiology table Platinum Néo, future key product of the company whose international launch starts during the 2nd semester 2022. The presentations of this new high-end table to radiologists will continue until the end of the year at the occasion of the professional trade shows Medica from November 14th to 17th in Düsseldorf (Germany) and Radiological Society of North America from November 27th to December 1st in Chicago (United States).

The company continues its progress in the MC2 project, aiming to develop two new high-end imaging solutions, an X-ray mobile and a C-arm for operating rooms manufactured in France, which will reinforce DMS Imaging's range of products by 2024. Consecutively to the conclusion of the strategic partnership with the company Micro-X for the supply of cold cathodes X-ray tubes, the integration tests of this technology in the X-ray mobile have been continuing in the 2nd semester 2022.

In Bone densitometry, the order book is good, and the group works to increase its production capacity in its new production and assembly unit to answer to customer request in the upcoming months.

The **DMS Biotech** division continues the strategy deployed since January 1st, 2022. The key recruitments are now over, and the team is now complete and operational. These investments will allow the DMS Biotech division to gain new market shares and thus secure its growth.

Presentation of the future strategic plan on October 25th, 2022

On Tuesday October 25th, 2022, Samuel Sancerni, Chief - Executive Officer of DMS Group, will report on the strategic review of all the Group's activities started last summer and will present the main axes of DMS Group's the future strategic plan, based on strengthening its position as a major European player in medical imaging.

Financial calendar for 2022

Date	Event
October 25 th , 2022	Presentation of the strategic plan (before Stock Exchange)
January 20 th , 2023	Publication of the 2022 annual turnover

The publications will be made when the Euronext Paris market is closed. These dates are given as an indication, they can be changed if necessary.



About DMS Group

DMS Group is composed of companies with a high innovation potential. Historically centered on medical imaging industry, the activity is developing in new directions. By investing on the future and betting on research, DMS Group hopes to bring the solutions of tomorrow.

- Specialized in high technology for medical diagnosis, **DMS Imaging** is now the French leader in development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology. DMS Imaging (previously ASIT Biotech) is quoted on the Euronext Brussels and Euronext Paris markets (ISIN: BE0974289218 - memo: DMSIM).
- **DMS Biotech** supports the development strategy of the group in the field of biotechnologies, and more specifically, technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of fat stem cells. Hybrigenics is quoted on the Paris Euronext Market (ISIN: FR0004153930 - memo: ALHYG).

DMS Group is on every continent through a network of over 140 national distributors, subsidiaries and joint ventures. DMS Group is quoted on the Paris Euronext market (ISIN: FR0012202497 - memo: DGM).

More information on www.dms.com.

FREE SUBSCRIPTION TO THE FINANCIAL INFORMATION OF DMS GROUP AT WWW.ACTUSNEWS.COM.

Contacts

DMS Group

Samuel SANCERNI CEO 04 67 50 49 00

ACTUS FINANCE

Mathieu OMNES Investors relations 01 53 67 36 92

Nawel NAAMANE Press Relations 01 53 67 36 34